# Verification of the Efficacy/safety of the Intratympanic Drug Delivery for Hearing Loss

> **NCT04766853** · PHASE1,PHASE2 · COMPLETED · sponsor: **Seoul National University Hospital** · enrollment: 15 (actual)

## Conditions studied

- Hearing Loss, Sudden
- Hearing Loss, Ototoxic
- Hearing Loss, Noise-Induced
- Meniere Disease

## Interventions

- **DRUG:** Dexamethasone
- **DRUG:** Hyaluronic acid

## Key facts

- **NCT ID:** NCT04766853
- **Lead sponsor:** Seoul National University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-07-22
- **Primary completion:** 2023-04-18
- **Final completion:** 2024-07-19
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2024-10-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04766853

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04766853, "Verification of the Efficacy/safety of the Intratympanic Drug Delivery for Hearing Loss". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04766853. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*